The native GLP-1 sequence has a very short half-life, and therapeutic advances have come from molecular engineering to alter the pharmacokinetic profile of synthetic GLP-1 receptor agonists to enable ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Q3 2024 Earnings Call Transcript November 6, 2024 WW International, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Q3 2024 Earnings Conference Call November 1, 2024 8:00 AM ETCompany ParticipantsCaspar Tudor – Head of Investor ...

Executives from Impact Analytics and Carters Inc. discuss demographic shifts, changing compositions, weight loss drugs and ...

ScioSense today launched a two-channel time-to-digital converter (TDC) which offers the very high time measurement resolution ...

McDonald's' strategy emphasizes its competitive strengths through a "MCD" framework: relevant marketing, core menu development, and the four Ds: digital, drive-thru, delivery, and development.

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

BigHat uses a sequence-based approach that requires hit ... starting with a once-monthly GLP-1 receptor agonist. Discover how AI is transforming the pharma commercial strategy.

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Find out what AI has already brought to Alzheimer's disease research and most importantly, what it can accomplish in the ...